David Nierengarten
Stock Analyst at Wedbush
(4.20)
# 466
Out of 5,042 analysts
206
Total ratings
51.79%
Success rate
14.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FATE Fate Therapeutics | Upgrades: Outperform | $5 → $7 | $1.35 | +418.52% | 16 | Oct 27, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $90 → $110 | $86.22 | +27.58% | 4 | Oct 17, 2025 | |
| ANAB AnaptysBio | Maintains: Outperform | $45 → $70 | $36.58 | +91.36% | 14 | Oct 15, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $800 → $880 | $818.50 | +7.51% | 22 | Oct 13, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $38 → $44 | $37.01 | +18.89% | 4 | Oct 13, 2025 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $6 | $5.22 | +14.94% | 11 | Oct 13, 2025 | |
| NUVL Nuvalent | Reiterates: Outperform | $115 | $99.32 | +15.79% | 6 | Sep 8, 2025 | |
| STTK Shattuck Labs | Initiates: Outperform | $4 | $1.89 | +111.64% | 1 | Sep 8, 2025 | |
| XNCR Xencor | Reiterates: Outperform | $26 | $14.69 | +76.99% | 8 | Sep 2, 2025 | |
| TLX Telix Pharmaceuticals | Reiterates: Outperform | $22 | $10.66 | +106.38% | 3 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $11.93 | +109.56% | 1 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $7 | $5.51 | +27.04% | 9 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $24.11 | -66.82% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $2.73 | +302.93% | 4 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $12.62 | -20.76% | 10 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $27 | $12.81 | +110.77% | 8 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 | $16.05 | +105.61% | 6 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $1.12 | +78.57% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $16.25 | +90.77% | 2 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $87 → $90 | $56.52 | +59.24% | 3 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $29.62 | +58.68% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $13.16 | +51.98% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $28.17 | +42.00% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $24.46 | +83.97% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.94 | +415.46% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $4.17 | +331.65% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $16.30 | -38.65% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $4.94 | +142.91% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $25.01 | +127.91% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $50 → $175 | $9.75 | +1,694.87% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $3.62 | +13,712.15% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $5.80 | +934.48% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $8.15 | +133.13% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $34.60 | +116.76% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.40 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $4.67 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.75 | - | 3 | Nov 20, 2017 |
Fate Therapeutics
Oct 27, 2025
Upgrades: Outperform
Price Target: $5 → $7
Current: $1.35
Upside: +418.52%
Disc Medicine
Oct 17, 2025
Maintains: Outperform
Price Target: $90 → $110
Current: $86.22
Upside: +27.58%
AnaptysBio
Oct 15, 2025
Maintains: Outperform
Price Target: $45 → $70
Current: $36.58
Upside: +91.36%
argenx SE
Oct 13, 2025
Maintains: Outperform
Price Target: $800 → $880
Current: $818.50
Upside: +7.51%
Kiniksa Pharmaceuticals International,
Oct 13, 2025
Maintains: Outperform
Price Target: $38 → $44
Current: $37.01
Upside: +18.89%
Nuvation Bio
Oct 13, 2025
Reiterates: Outperform
Price Target: $6
Current: $5.22
Upside: +14.94%
Nuvalent
Sep 8, 2025
Reiterates: Outperform
Price Target: $115
Current: $99.32
Upside: +15.79%
Shattuck Labs
Sep 8, 2025
Initiates: Outperform
Price Target: $4
Current: $1.89
Upside: +111.64%
Xencor
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $14.69
Upside: +76.99%
Telix Pharmaceuticals
Aug 28, 2025
Reiterates: Outperform
Price Target: $22
Current: $10.66
Upside: +106.38%
Aug 18, 2025
Initiates: Outperform
Price Target: $25
Current: $11.93
Upside: +109.56%
Aug 13, 2025
Downgrades: Neutral
Price Target: $7
Current: $5.51
Upside: +27.04%
Jun 26, 2025
Reiterates: Neutral
Price Target: $8
Current: $24.11
Upside: -66.82%
Jun 23, 2025
Reiterates: Outperform
Price Target: $11
Current: $2.73
Upside: +302.93%
May 19, 2025
Reiterates: Neutral
Price Target: $10
Current: $12.62
Upside: -20.76%
Apr 16, 2025
Maintains: Neutral
Price Target: $29 → $27
Current: $12.81
Upside: +110.77%
Mar 20, 2025
Reiterates: Outperform
Price Target: $33
Current: $16.05
Upside: +105.61%
Mar 14, 2025
Downgrades: Neutral
Price Target: $8 → $2
Current: $1.12
Upside: +78.57%
Feb 12, 2025
Reiterates: Outperform
Price Target: $31
Current: $16.25
Upside: +90.77%
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $56.52
Upside: +59.24%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $29.62
Upside: +58.68%
Sep 10, 2024
Reiterates: Outperform
Price Target: $20
Current: $13.16
Upside: +51.98%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $28.17
Upside: +42.00%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $24.46
Upside: +83.97%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.94
Upside: +415.46%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $4.17
Upside: +331.65%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $16.30
Upside: -38.65%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $4.94
Upside: +142.91%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $25.01
Upside: +127.91%
Feb 29, 2024
Upgrades: Outperform
Price Target: $50 → $175
Current: $9.75
Upside: +1,694.87%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $3.62
Upside: +13,712.15%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $5.80
Upside: +934.48%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $8.15
Upside: +133.13%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $34.60
Upside: +116.76%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.40
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $4.67
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $10.75
Upside: -